(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 25.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.28%.
Arcutis Biotherapeutics's revenue in 2025 is $317,929,000.On average, 10 Wall Street analysts forecast ARQT's revenue for 2025 to be $44,604,306,795, with the lowest ARQT revenue forecast at $42,447,219,294, and the highest ARQT revenue forecast at $46,468,637,957. On average, 10 Wall Street analysts forecast ARQT's revenue for 2026 to be $58,296,484,017, with the lowest ARQT revenue forecast at $55,459,564,850, and the highest ARQT revenue forecast at $60,462,145,971.
In 2027, ARQT is forecast to generate $76,106,848,733 in revenue, with the lowest revenue forecast at $68,698,520,961 and the highest revenue forecast at $89,002,826,707.